Product Lines

Along with VALSARTAN the Company has other products ready for market deployment.

Brimonidine Tartrate

It is a new medicine for Anti-glaucoma and is produced solely by the Company as a medicine for the adrenaline receptors of an idiosyncrasy. It is mainly intended for diseases of an open glaucoma or high eye pressure.

Brimonidine Tartrate Eyes Drops

This is an anti-glaucoma medicine used for medical care and produced solely by our Company as a medicine for the adrenaline receptors of an idiosyncrasy a2. And it is mainly intended for diseases of open glaucoma or high eye pressure and high eye pressure as a side effect of ATL. The medicine was first put into market in America in 1998 and only in February 2, 1999, had our Company received the legitimacy to produce it and put it into the domestic market. A fast and obvious curative effect, very few side effects, a very high exponent of cure and high endurement are prime features of the drug. It will produce no harmful effects of reducing blood pressure, resulting in calmness and so on, much like diazepam.

Leflunomide

Leflunomide is a medicine for the treatment of rheumatoid arthritis, systematically erythematic lupus, and psoriasis. It also has functions such as anti-rejection. It is among the first-rate new medications on today’s market in China

Levofloxacin Lactate for Injection

Levofloxacin is a popular anti-bacterial drug with indications of all kinds of bacterial inflections and used for medical care. In face of the fierce competition in the market, our Company attaches great importance on quality and improvement in production, adhering to the principle that “no quality results in no survival”. Besides, it has also established a stably cooperative relationship with scientific research institutes on new medicine such as the Chinese Academy of Medicine and Chinese Academy for Traditional Chinese Medicine, as well as national inspection organs on drug quality, which lays a solid foundation for the development of the Company.

This website contains forward-looking statements that involve risks and uncertainties, including those relating to the Company's ability to grow its business. Actual results may differ materially from the results predicted and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the company's limited operating history, the limited financial resources, domestic or global economic conditions -- especially those relating to China, activities of competitors and the presence of new or additional competition, and changes in Federal or State laws, restrictions and regulations on doing business in a foreign country, in particular China, and conditions of equity markets. More information about the potential factors that could affect the company's business and financial results is included in the Company's filings, available via the United States Securities & Exchange Commission. Occasionally, the Company may select and post articles or opinions of third parties, with no known connection with the Company. These are considered expert or qualified writers about the Chinese economy and its various opportunities and pitfalls. The Company neither endorses nor rejects these views or content, and the articles are offered only for the readers' edification and personal analyses.